Prospects for Alzheimer’s disease monitoring and treatment in 2023

Stephen P. Salloway, MD, MS, Butler Hospital & Warren Alpert Medical School of Brown University, Providence, RI, reviews the prospects for Alzheimer’s disease treatment in 2023. The rapid developments seen in the anti-amyloid treatment space are set to continue, as release of the Phase III donanemab data is expected this year, as well as a decision by the FDA on whether to grant full approval of lecanemab. The Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) is a new domain this year, designed for monitoring the safety and efficacy of disease modifying therapies in clinical practice. The network will collect real-world longitudinal evidence from individuals treated with new FDA-approved therapies, which will be used by health care providers and researchers to improve patient care and guide future treatments. Finally, new blood tests that assess amyloid ratios and isomers of phosphorylated tau (p-tau) are becoming increasingly available, for clinical trial screening and diagnostics. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.